Diverse patent strategies essential, foreign lawyer says

Published: 2011-04-28 06:57:00

Updated: 2011-04-28 06:57:00

Korean drug companies who intend to make inroad to the U.S. market need to make a careful review on patents listed in the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) as part of plan to avoid any possible patent suits there, a foreign lawyer said Tuesday.

In an...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK